JPWO2021151984A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021151984A5 JPWO2021151984A5 JP2022546059A JP2022546059A JPWO2021151984A5 JP WO2021151984 A5 JPWO2021151984 A5 JP WO2021151984A5 JP 2022546059 A JP2022546059 A JP 2022546059A JP 2022546059 A JP2022546059 A JP 2022546059A JP WO2021151984 A5 JPWO2021151984 A5 JP WO2021151984A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nectin
- composition according
- individual
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077110A JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968175P | 2020-01-31 | 2020-01-31 | |
| US62/968,175 | 2020-01-31 | ||
| PCT/EP2021/051938 WO2021151984A1 (en) | 2020-01-31 | 2021-01-28 | Treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077110A Division JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023512036A JP2023512036A (ja) | 2023-03-23 |
| JP2023512036A5 JP2023512036A5 (https=) | 2024-02-05 |
| JPWO2021151984A5 true JPWO2021151984A5 (https=) | 2024-02-05 |
| JP7682553B2 JP7682553B2 (ja) | 2025-05-26 |
Family
ID=74494891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546059A Active JP7682553B2 (ja) | 2020-01-31 | 2021-01-28 | 癌の処置 |
| JP2025077110A Pending JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077110A Pending JP2025121970A (ja) | 2020-01-31 | 2025-05-07 | 癌の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12594343B2 (https=) |
| EP (2) | EP4512478A3 (https=) |
| JP (2) | JP7682553B2 (https=) |
| CN (1) | CN114845740A (https=) |
| AU (2) | AU2021213421B2 (https=) |
| CA (1) | CA3160557A1 (https=) |
| DK (1) | DK4096717T3 (https=) |
| ES (1) | ES3014740T3 (https=) |
| WO (1) | WO2021151984A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022058395A1 (en) * | 2020-09-15 | 2022-03-24 | Synaffix B.V. | Antibody-exatecan conjugates |
| CA3196198A1 (en) * | 2020-11-25 | 2022-06-02 | Manel KRAIEM | Treatment of cancer |
| EP4086284A1 (en) * | 2021-05-07 | 2022-11-09 | Emergence Therapeutics AG | Anti-nectin-4 antibody exatecan conjugates |
| CR20230470A (es) * | 2021-03-31 | 2023-11-30 | Univ Aix Marseille | Conjugados de anticuerpo anti-nectina-4 y exatecano. |
| CN117500528A (zh) * | 2021-06-18 | 2024-02-02 | 北京海步医药科技有限公司 | 连接子及其缀合物 |
| CN118450907A (zh) * | 2021-12-28 | 2024-08-06 | 百济神州有限公司 | 抗体药物结合物 |
| EP4496593A1 (en) * | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
| CA3245954A1 (en) * | 2022-05-25 | 2023-11-30 | Innate Pharma | NECTIN-4 LIAISON OFFICERS |
| EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| US20230408497A1 (en) * | 2022-06-20 | 2023-12-21 | Sysmex Corporation | Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance |
| WO2024012541A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| JP2025525518A (ja) * | 2022-07-14 | 2025-08-05 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 抗Ｎｅｃｔｉｎ－４抗体、その抗体薬物コンジュゲート及び応用 |
| EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| WO2024028258A1 (en) * | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| EP4324849A1 (en) * | 2022-08-18 | 2024-02-21 | Emergence Therapeutics AG | Humanized anti-nectin-4 antibodies |
| EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
| PE20252282A1 (es) * | 2022-10-09 | 2025-09-18 | Lanova Medicines Ltd | Compuestos, composiciones y metodos |
| CN120417935A (zh) * | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| AU2023377443A1 (en) * | 2022-11-09 | 2025-05-08 | Obi Pharma, Inc. | Glycosynthase variants for antibody-drug conjugate engineering |
| WO2024191598A1 (en) * | 2023-03-10 | 2024-09-19 | Emory University | Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| EP4727971A1 (en) * | 2023-06-13 | 2026-04-22 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| WO2025003396A1 (en) * | 2023-06-28 | 2025-01-02 | Université De Tours | Pegylated linkers and uses thereof |
| TW202530249A (zh) * | 2023-09-29 | 2025-08-01 | 美商雅克提斯腫瘤學公司 | 小蛋白、結合物及其用途 |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| WO2025078881A2 (en) * | 2023-10-13 | 2025-04-17 | Ligachem Biosciences Inc. | Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof |
| US20250121084A1 (en) * | 2023-10-17 | 2025-04-17 | Adc Therapeutics Sa | Anti-claudin-6 conjugates |
| FR3155708A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| FR3155709A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| AU2024394903A1 (en) * | 2023-12-06 | 2026-04-02 | Adc Therapeutics Sa | Anti-psma antibody drug conjugates comprising exatecan |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| FR3164899A1 (fr) * | 2024-07-24 | 2026-01-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| HK1040052B (zh) * | 1998-05-22 | 2006-09-15 | 第一制药株式会社 | 药物复合物 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| AU2003240482B2 (en) | 2002-05-30 | 2009-03-12 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| JP2006507322A (ja) | 2002-11-14 | 2006-03-02 | シンタルガ・ビーブイ | 多重自己脱離放出スペーサーとして構築されたプロドラッグ |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| CN104529711B (zh) | 2007-11-21 | 2020-02-07 | 乔治亚大学研究基金公司 | 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法 |
| US20110301056A1 (en) | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| US20130005678A1 (en) | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| EP3409287B9 (en) | 2010-09-29 | 2021-07-21 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| US9764038B2 (en) | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| WO2016053107A1 (en) | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| US10675357B2 (en) | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
| ES2921236T3 (es) | 2016-11-25 | 2022-08-22 | Mabwell Shanghai Bioscience Co Ltd | Enlazador de amida maleica disustituida para la conjugación de anticuerpo y fármaco y método de preparación y uso del mismo |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| CN111675761B (zh) | 2017-06-05 | 2023-10-20 | 艾更斯司股份有限公司 | 柄蛋白-4结合蛋白及其使用方法 |
| JP7551056B2 (ja) | 2017-10-05 | 2024-09-17 | ソニーグループ株式会社 | プログラマブルなポリマー薬物 |
| JP7381478B2 (ja) * | 2017-10-23 | 2023-11-15 | マブリンク ビオシオンス | 単一分子量ポリサルコシンを含むリガンド－薬物－複合体 |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CN112543771B (zh) | 2018-09-30 | 2023-04-11 | 江苏豪森药业集团有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
| JP7629902B2 (ja) | 2019-03-19 | 2025-02-14 | パウル・シェラー・インスティトゥート | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| JP7561141B2 (ja) * | 2019-04-26 | 2024-10-03 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
| JP7167163B2 (ja) | 2019-05-20 | 2022-11-08 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス |
| JP2022551537A (ja) | 2019-10-07 | 2022-12-09 | ユニヴェルシテ デクス－マルセイユ | ネクチン－４に対する特異性を有する抗体及びその使用 |
| CA3162282A1 (en) | 2019-11-25 | 2021-06-03 | Agensys, Inc. | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| CN113527486B (zh) | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| CA3182395A1 (en) | 2020-06-18 | 2021-12-23 | Jay M. Short | Conditionally active anti-nectin-4 antibodies |
| US20230331867A1 (en) | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| WO2022058395A1 (en) | 2020-09-15 | 2022-03-24 | Synaffix B.V. | Antibody-exatecan conjugates |
| CA3196198A1 (en) | 2020-11-25 | 2022-06-02 | Manel KRAIEM | Treatment of cancer |
| CA3245954A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | NECTIN-4 LIAISON OFFICERS |
-
2021
- 2021-01-28 AU AU2021213421A patent/AU2021213421B2/en active Active
- 2021-01-28 CN CN202180007603.2A patent/CN114845740A/zh active Pending
- 2021-01-28 ES ES21702624T patent/ES3014740T3/es active Active
- 2021-01-28 DK DK21702624.4T patent/DK4096717T3/da active
- 2021-01-28 EP EP24211980.8A patent/EP4512478A3/en active Pending
- 2021-01-28 US US17/796,707 patent/US12594343B2/en active Active
- 2021-01-28 JP JP2022546059A patent/JP7682553B2/ja active Active
- 2021-01-28 CA CA3160557A patent/CA3160557A1/en active Pending
- 2021-01-28 EP EP21702624.4A patent/EP4096717B1/en active Active
- 2021-01-28 WO PCT/EP2021/051938 patent/WO2021151984A1/en not_active Ceased
-
2025
- 2025-04-14 AU AU2025202617A patent/AU2025202617A1/en active Pending
- 2025-05-07 JP JP2025077110A patent/JP2025121970A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021151984A5 (https=) | ||
| Tarantino et al. | Optimizing the safety of antibody–drug conjugates for patients with solid tumours | |
| Wolska-Washer et al. | Safety and tolerability of antibody-drug conjugates in cancer | |
| Ashman et al. | Non-internalising antibody–drug conjugates | |
| Fu et al. | DNA damaging agent-based antibody-drug conjugates for cancer therapy | |
| Trail et al. | Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design | |
| Lambert et al. | Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review | |
| Kratz et al. | Prodrug strategies in anticancer chemotherapy | |
| CN116440279B (zh) | 包含抗folr1免疫缀合物的治疗组合 | |
| US20230330258A1 (en) | Conjugates comprising a phosphorus (v) and a drug moiety | |
| Singh et al. | A new triglycyl peptide linker for antibody–drug conjugates (ADCs) with improved targeted killing of cancer cells | |
| Lee et al. | Antibody-drug conjugates in gynecologic malignancies | |
| US20170028080A1 (en) | Targeted Drug Conjugates | |
| WO2018154517A1 (en) | Immunocytokine combination therapy | |
| WO2021228044A1 (en) | Drug conjugates containing alpha-enolase antibodies and uses thereof | |
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| Xie et al. | Antibody-drug conjugates for the therapy of thoracic malignancies | |
| Zhang et al. | Evaluation of double self-immolative linker-based antibody–drug conjugate FDA022-BB05 with enhanced therapeutic potential | |
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Cheng et al. | Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors | |
| Deng et al. | Recent advances in antibody-drug conjugates for breast cancer treatment | |
| Sevilla-Carrillo et al. | Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology | |
| Mathi et al. | Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy | |
| Abbas et al. | Antibody‐Drug Conjugates Used in Breast Cancers | |
| Guffroy et al. | Improving the safety profile of ADCs |